WHC is still in active development. Read this to understand our approach.
depiction of LDXDSHIEDAPSSA-UHFFFAOYSA-N.svg
isomerdesign

Ramatroban

Verificar en isomerdesign

drugmap

Ramatroban

Verificar en drugmap

Data

InChI: InChI=1S/C21H21FN2O4S/c22-14-5-8-16(9-6-14)29(27,28)23-15-7-10-20-18(13-15)17-3-1-2-4-19(17)24(20)12-11-21(25)26/h1-6,8-9,15,23H,7,10-13H2,(H,25,26)

Sinónimos: Bay-u-3405, [3H]ramatroban, BAY u3405, 3-(4-Fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazole propanoic acid, Baynas, CHEMBL361812, 3-[(3R)-3-[(4-fluorophenyl)sulfonylamino]-1,2,3,4-tetrahydrocarbazol-9-yl]propanoic acid, P1ALI72U6C, DSSTox_RID_81819, Baynas (TN), C21H21FN2O4S, Bay u 3406, Bay u 3405, UNII-P1ALI72U6C, Ramatroban (JAN/INN), BAY-u 3405, EN-137774, (+)-(3R)-3-(p-Fluorobenzenesulfonamido)-1,2,3,4-tetrahydrocarbazole-9-propionic acid,116649-85-5,Ramatroban, Bay u-3405, NCGC00167519-01

Estimated data

Solubilidad: -4.189 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: No (prediction using frontiersin.org)

Addictivity Prediction: 38.8% (prediction based on www.mdpi.com)

Similitudes

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.